Tag

Waters

All articles tagged with #waters

FDA clears Waters' at-home HPV screening to speed cervical cancer detection
health1 day ago

FDA clears Waters' at-home HPV screening to speed cervical cancer detection

The U.S. FDA has cleared Waters’ at-home cervical cancer screening kit for use with an approved HPV test, enabling patients to self-collect samples at home and mail them to a laboratory. The kit, tested with BD’s Onclarity HPV assay, targets high-risk HPV types and aims to improve early detection and reduce cervical cancer deaths, with Waters planning nationwide availability by prescription and anticipated insurance coverage.

Waters' ‘Can you shut him up?’ moment spotlights tariffs and inflation debate
business2 months ago

Waters' ‘Can you shut him up?’ moment spotlights tariffs and inflation debate

During a House Financial Services hearing, Rep. Maxine Waters pressed Treasury official Scott Bessent as he argued tariffs are not inflationary, while Waters warned tariffs have raised prices on goods and housing costs. Analysts note tariffs can create one-time price increases and financial uncertainty, whereas unemployment tends to spike briefly before easing. The discussion also touches on housing affordability, with lumber prices and immigration cited as factors in supply and demand. The piece frames tariffs’ real-world impact as central to voters’ views on affordability ahead of the 2026 elections.

Waters to Acquire Becton Dickinson's Diagnostics Unit in $17.5 Billion Merger
business9 months ago

Waters to Acquire Becton Dickinson's Diagnostics Unit in $17.5 Billion Merger

Waters Corp is acquiring a Becton Dickinson bioscience and diagnostics unit in a $17.5 billion stock-and-cash deal, aiming to expand its presence in clinical and diagnostic markets, while Becton Dickinson exits a tariff-sensitive segment to focus on core medtech. The deal, structured through a Reverse Morris Trust, will result in Waters owning 61% of the new company, with Becton Dickinson shareholders holding 39%, but has faced skepticism from investors due to execution risks.